{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.2","upperLimit":"9.1","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"The event-free survival time is defined as the time from registration to disease progression (PD=Increase of \\> 25% from lowest response value in Serum/Urine M-component) while receiving bendamustine, lenalidomide, and dexamethasone, death due to any cause, or subsequent treatment for multiple myeloma. The distribution of event-free survival will be estimated using the method of Kaplan-Meier. Treatment response was assessed using the International Myeloma Working Group uniform criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine 75 mg/m\\^2 IV day 1 and 2 Lenalidomide 25 mg PO days 1-21 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Maximum Tolerated Dose, Dose Level 4"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years from study completion","title":"Event Free Survival (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}